Eagle Rock Investment Company’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.34M Hold
5,335
0.17% 84
2026
Q1
$1.16M Sell
5,335
-50
-0.9% -$11.1K 0.17% 90
2025
Q4
$1.23M Hold
5,385
0.17% 90
2025
Q3
$1.25M Hold
5,385
0.18% 90
2025
Q2
$1,000K Sell
5,385
-46
-0.8% -$8.55K 0.16% 93
2025
Q1
$1.14M Sell
5,431
-252
-4% -$49K 0.2% 92
2024
Q4
$1.01M Sell
5,683
-189
-3% -$34.7K 0.17% 93
2024
Q3
$1.16M Sell
5,872
-160
-3% -$29.9K 0.19% 92
2024
Q2
$1.03M Hold
6,032
0.19% 93
2024
Q1
$1.1M Hold
6,032
0.2% 92
2023
Q4
$935K Hold
6,032
0.19% 91
2023
Q3
$899K Hold
6,032
0.2% 88
2023
Q2
$813K Sell
6,032
-936
-13% -$137K 0.18% 91
2023
Q1
$1.11M Sell
6,968
-150
-2% -$22.9K 0.26% 81
2022
Q4
$1.12M Sell
7,118
-6,148
-46% -$943K 0.26% 86
2022
Q3
$1.78M Sell
13,266
-407
-3% -$58.4K 0.46% 58
2022
Q2
$2.09M Sell
13,673
-5,883
-30% -$899K 0.51% 49
2022
Q1
$3.17M Sell
19,556
-19,936
-50% -$2.9M 0.67% 41
2021
Q4
$5.35M Buy
+39,492
New +$4.67M 1.02% 38

Other funds holding ABBV

Eagle Rock Investment Company's ABBV Position: Q2 2026 in Review

Eagle Rock Investment Company held its AbbVie (ABBV) position steady in Q2 2026 at 5,335 shares worth $1.34M. The position accounts for 0.17% of the portfolio, ranked #84.

Eagle Rock Investment Company first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $5.35M in Q4 2021. 1,882 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Eagle Rock Investment Company held 5,335 shares of AbbVie worth $1.34M as of Q2 2026.
  • Eagle Rock Investment Company left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.17% of Eagle Rock Investment Company's portfolio in Q2 2026, its #84 holding.
  • Eagle Rock Investment Company first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • Eagle Rock Investment Company's AbbVie position peaked at $5.35M in Q4 2021.
  • 1,882 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Eagle Rock Investment Company's 13F filing for Q2 2026, filed 9 Jul 2026.